Think You Have A “Breakthrough” Drug? Think Again, FDA’s Woodcock Says
Executive Summary
CDER director says breakthrough designation requests are frequently denied because evidence suggests only an incremental advance over standard therapy; other reasons for denial include showing no clinical advantage and a development program being placed on clinical hold.